A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck
Upon determination of eligibility, patients will receive:
Induction Therapy
- Docetaxel
- Carboplatin
- 5-FU
- Gefitinib
Combined Modality Therapy
Cohort 1:
- Radiation therapy
- Gefitinib
Cohort 2:
- Radiation therapy
- Gefitinib
- Docetaxel
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI HN 04
NCT00193284
October 2003
January 2009
Name | Location |
---|---|
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |